Gerresheimer continues on its growth path and reports a good half-year result. Sales grew organically by around 17 percent excluding currency effects and reached €957 million. Following the successful realignment of the product mix, the company is clearly benefiting from global megatrends in the pharma and biotech market.
In particular for biopharmaceutics, including the new drugs based on the peptide hormone GLP-1 (glucagon-like peptide 1) for the treatment of obesity, Gerresheimer offers a broad solution portfolio and has already secured long-term orders. For its planned further growth, the company is currently expanding its production capacities in Europe, the USA and Mexico. The focus here is primarily on medical systems, including syringes, pens and auto-injectors, as well as high value solutions.
“As a result of our focus on innovation, excellence, and sustainability, we are today the strategic partner of choice for the global pharma and biotech industry,” said Dietmar Siemssen, CEO of Gerresheimer. “We benefit from demand for both containment solutions and innovative drug delivery solutions for new biopharmaceuticals. We have the right systems, solutions, and services and are investing today in the profitable growth of tomorrow.”
In the first half of 2023, the Plastics & Devices Division achieved sales revenues of 494 million euros compared to €414 million in the previous year and thus grew organically by 18 percent. Demand for plastic containment solutions and medical devices, especially inhalers and pens, contributed to this very good development.
The Primary Packaging Glass Division achieved a sales increase of almost 16 per cent to around €462 million in H1 2023, compared to around €400 million in H1 2021, benefiting from strong performance in both the Moulded Glass and Tubular Glass businesses. Demand for High Value Solutions remained at a high level.
For the second half of 2023, the company anticipates a continued positive business development and confirmed its full-year forecast. Thus, at least ten percent organic sales growth is to be achieved in the financial year 2023. The company also expects the same growth target for sales in the medium term.